How Nvidia AI is Powering Global Healthcare Partnerships

AI adoption in healthcare is in higher demand as the sector confronts workforce challenges and increasing demands for patient care.

The integration of foundation models into clinical workflows is shifting from traditional automation to systems capable of complex decision-making in areas from drug discovery to patient diagnosis.

This is a result of AI enabling healthcare providers to process vast quantities of medical data, from genomic sequences to pathology images, while maintaining regulatory compliance and patient privacy standards.

These developments are happening as healthcare organisations worldwide seek solutions to address staffing pressures and rising costs.

According to the World Health Organisation, the healthcare sector faces a shortage of 10 million workers by 2030, which is driving organisations to implement AI systems across research, drug development and patient care.

Taking on this challenge, Nvidia has announced partnerships with four healthcare organisations at the JP Morgan Healthcare Conference in San Francisco to advance drug discovery, pathology, genomic research and clinical workflows through foundation models and agentic AI, which enables automated decision-making processes.

Nvidia Cosmos platform drives healthcare innovation

Jensen Huang, Founder and CEO of Nvidia, unveiled Nvidia Cosmos, which is a physical AI platform that includes foundation models to predict robot actions.

These models use similar techniques to language models (LMs) that predict the next word in a sentence.

"The future of AI is likely to involve a fair amount of thinking," he said.

"The ability for AI to now reason, plan and act is foundational to the way we're going to go forward."

Jensen also outlines the progression of AI capabilities: "The idea that you can generate the next frame for a video has become common sense.

“And if that's the case, is it possible that generating the next articulation could be common sense? And the answer is absolutely."

Mayo Clinic deploys Nvidia systems for cancer research

Mayo Clinic, the US-based research hospital, will apply Nvidia's computing technology to its pathology database to develop AI systems for cancer care.

Christina Zorn, Chief Administrative Officer at Mayo Clinic, says: "We saw a paradigm shift in healthcare. You're either going to disrupt from within or you're going to be disrupted."

Christina also outlines Mayo Clinic's strategy to address healthcare worker shortages through robotics implementation: "We're going to use, essentially, the robots to be a member of the healthcare team in the healthcare spaces.

“We knew we had to embrace tech in a way that was really going to optimise everything we do."

Arc Institute develops foundation models for genomics

The Arc Institute, a non-profit research organisation, provides multiyear funding for researchers to focus on innovation rather than grant writing.

The institute has developed Evo, a foundation model that processes DNA, RNA and protein information.

Patrick Collison, Co-founder of payment technology company Stripe and the Arc Institute, says: "A lot of the low-hanging fruit, the stuff that is easier to discover, we did. Today, it's immensely harder."

The institute also works with Nvidia to advance drug discovery and disease research applications through foundation models for biology.

Jacob Thaysen, CEO of DNA sequencing technology company Illumina also says: "Combining other information, other modalities, other 'omics' is going to give us much deeper insight into biology.

“But while DNA was difficult itself, when you then combine all the omics, it becomes exponentially more challenging. It's getting so complicated that we do need huge computing power and AI to really understand and process it."

Nvidia launches healthcare developer resources

Kimberly Powell, Nvidia's Vice President of Healthcare, additionally announced new resources including Nvidia NIM microservice for GenMol, a system for molecular generation and Nvidia BioNeMo Blueprint for protein design.

These tools form part of Nvidia Blueprints, a collection of workflows for agentic and Gen AI applications.

Meanwhile, IQVIA, a clinical research and commercial services provider, collaborates with Nvidia to develop foundation models for healthcare data analysis.

These models aim to reduce manual processes in clinical trials and therapy launches while maintaining privacy, regulatory compliance and patient safety standards.

Ari Bousbib, Chairman and CEO of IQVIA, adds: "The opportunity here is to try to reduce the dependencies and sequential series of steps that require a lot of interactions and handle them without human touch.

“AI agents will be able to eliminate the white space, that is, the time waiting for humans to complete those tasks."

Explore the latest edition of Technology Magazine and be part of the conversation at our global conference series, Tech & AI LIVE.

Discover all our upcoming events and secure your tickets today.

Technology Magazine is a BizClik brand